Related Experiment Video
Updated: Apr 29, 2026
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Molecular markers for patients with thymic malignancies: not feasible at present?
Nilufer Avci1, Gulsah Cecener, Adem Deligonul
1Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa, Turkey
Background:
Thymomas and thymic carcinomas are rare malignancies and devising clinically effective molecular targeted therapies is a major clinical challenge. The aim of the study was to analyze BLC2 and vascular endothelial growth factor receptor (VEGFR) expression and KRAS and EGFR mutational status and to correlate them with the clinical characteristics of patients with thymomas and thymic carcinomas.
Materials And Methods:
A total of 62 patients (mean age: 50.4 ± 13.2 years) with thymomas and thymic carcinomas were enrolled. The expression of BLC2 and VEGFR in tumor cells and normal tissues was evaluated by RT-PCR. The mutational status of the KRAS and EGFR genes was investigated by PCR with sequence specific primers.
Results:
The BLC2 and VEGFR expression levels did not differ significantly between tumor and normal tissues. Moreover, there were no clearly pathogenic mutations in KRAS or EGFR genes in any tumor. None of the molecular markers were significantly related to clinical outcomes.
Conclusions:
Changes in levels of expression of BLC2 and VEGFR do not appear to be involved in thymic tumorigenesis. Moreover, our data suggest that KRAS and EGFR mutations do not play a major role in the pathogenesis of thymomas and thymic carcinomas.
Insights
This study found no significant differences in BCL2 and VEGFR expression or KRAS/EGFR mutations in thymomas and thymic carcinomas. These molecular markers do not appear to be involved in thymic cancer development or progression.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Thymomas and thymic carcinomas are rare malignancies.
- Developing targeted therapies for these cancers is challenging.
- Understanding molecular drivers is crucial for treatment development.
Purpose of the Study:
- To analyze BCL2 and VEGFR expression in thymic tumors.
- To investigate KRAS and EGFR mutational status.
- To correlate these molecular markers with clinical characteristics.
Main Methods:
- Analyzed 62 patients with thymomas and thymic carcinomas.
- Evaluated BCL2 and VEGFR expression using RT-PCR.
- Investigated KRAS and EGFR mutations via PCR.
Main Results:
- No significant difference in BCL2 and VEGFR expression between tumor and normal tissues.
- No pathogenic KRAS or EGFR mutations were detected.
- Molecular markers showed no significant correlation with clinical outcomes.
Conclusions:
- BCL2 and VEGFR expression changes are not implicated in thymic tumorigenesis.
- KRAS and EGFR mutations do not seem to play a significant role in thymic cancer pathogenesis.
